Drug profile

The FDA adverse-event record for Glucosamine + Chondroitin

424 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Glucosamine + Chondroitin. See the species affected, top reactions, and outcomes below.

424
adverse-event reports
5.9%
death-coded share
Dog
most-reported species
89
Emesis - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
424
Total Reports
25
Deaths Reported
5.9%
Death Rate

Active Ingredients

Glucosamine + Chondroitin

Administration Routes

OralUnknownAuricular (Otic)

Species Affected

Dog 394
Cat 28
Human 2

Most Affected Breeds

Retriever - Labrador 75
Retriever - Golden 30
Crossbred Canine/dog 25
Domestic Shorthair 18
Shepherd Dog - German 12
Shepherd Dog - Australian 11
Pit Bull 10
Boxer (German Boxer) 9
Terrier - Yorkshire 9
Rottweiler 9

Most Reported Reactions

Emesis 89
Vomiting 78
Lethargy (see also Central nervous system depression in 'Neurological') 65
Diarrhoea 35
Lack of efficacy - NOS 32
Other abnormal test result NOS 26
Behavioural disorder NOS 23
Anorexia 21
Weight loss 19
Seizure NOS 17
Not eating 17
Decreased appetite 17

Outcome Breakdown

Recovered/Normal
182 (42.9%)
Outcome Unknown
105 (24.8%)
Ongoing
79 (18.6%)
Recovered with Sequela
33 (7.8%)
Euthanized
16 (3.8%)
Died
9 (2.1%)

Glucosamine + Chondroitin Adverse Event Insights

424 reports name Glucosamine + Chondroitin; 25 recorded a death outcome (5.9% of reported events, not a population-level mortality rate). Active ingredient: Glucosamine + Chondroitin. Administration routes: Oral, Unknown, Auricular (Otic).

By species: Dog (394 reports), Cat (28 reports), Human (2 reports). By breed: Retriever - Labrador (75), Retriever - Golden (30), Crossbred Canine/dog (25).

Leading clinical signs: Emesis (89), Vomiting (78), Lethargy (see also Central nervous system depression in 'Neurological') (65), Diarrhoea (35). Outcome, 424 coded reports: Recovered/Normal leads at 42.9%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.